<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="common with COVID19 and associated therapies that could be worth" exact="testing" post="in the context of clinical trials. Here we discuss"/>
 <result pre="discuss these diseases, their management, and potential applications of these" exact="treatment" post="in the context of COVID-19. We also discuss current"/>
 <result pre="discuss current cellular therapies that are being evaluated for the" exact="treatment" post="of COVID-19 and/or its associated symptoms. Key Words cellular"/>
 <result pre="[4]. Recently, a cohort of 21 patients with confirmed COVID-19" exact="infection" post="and severe disease showed markedly elevated blood levels of"/>
 <result pre="(IL)-6, high C-reactive protein and soluble CD25 suggest that SARS-CoV-2" exact="infection" post="may trigger cytokine storm syndrome. This hyper-reactive cytokine release"/>
 <result pre="observed after CAR-T cell therapy; as such, identification, grading and" exact="treatment" post="of this complication has been well described in recent"/>
 <result pre="five of eight criteria must be present to make the" exact="diagnosis" post="of HLH IRIS is another hyperinflammatory syndrome with pathogenesis"/>
 <result pre="antiretrovirals and presenting as worsened clinical manifestations of a preexisting" exact="infection" post="or unmasking of a clinically silent infection [11]. Another"/>
 <result pre="of a preexisting infection or unmasking of a clinically silent" exact="infection" post="[11]. Another condition in which antimicrobial treatment may trigger"/>
 <result pre="a clinically silent infection [11]. Another condition in which antimicrobial" exact="treatment" post="may trigger IRIS is Whipple's disease, a chronic infection"/>
 <result pre="antimicrobial treatment may trigger IRIS is Whipple's disease, a chronic" exact="infection" post="due to Tropheryma whipplei that develops in immunologically susceptible"/>
 <result pre="initial reduction in CD4+ cell counts and their reconstitution on" exact="treatment" post="is more pronounced in those patients who developed IRIS"/>
 <result pre="alloimmune-mediated lung syndromes [16]. It remains to be ascertained whether" exact="treatment" post="of COVID-19 in susceptible immunocompromised hosts may trigger IRIS."/>
 <result pre="and children. The optimal dose and schedule of tocilizumab for" exact="treatment" post="of CAR-T-cellâ€&quot;induced CRS is not known, but dosing instructions"/>
 <result pre="being systematically studied. The efficacy of IL-6â€&quot;IL-6R antagonists for the" exact="treatment" post="of CRS as well as sHLH underscores the central"/>
 <result pre="its efficacy. Siltuximab has not been sufficiently studied as a" exact="treatment" post="for CRS and its use remains investigational; therefore, it"/>
 <result pre="clinical setting [31]. Although they show great promise in the" exact="treatment" post="of many immune and inflammatory disorders, the large variability"/>
 <result pre="parallel with studies evaluating the potency of MSC for the" exact="treatment" post="COVID-19 in China, there are now several centers globally"/>
 <result pre="HLA match [64]. This would allow for rapid shipment and" exact="treatment" post="of patients, albeit in hospitals with existing cell therapy"/>
 <result pre="there are several issues including but not limited to source," exact="isolation" post="and purification approaches, manufacturing consistency and potency that are"/>
 <result pre="World Health Organization on clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus infection is suspected advises against the"/>
 <result pre="clinical management of severe acute respiratory infection when novel coronavirus" exact="infection" post="is suspected advises against the use of corticosteroids unless"/>
 <result pre="impair complement-dependent antigen-antibody reactions. Chloroquine has been used for malaria" exact="treatment" post="and chemoprophylaxis and hydroxychloroquine is used for treatment of"/>
 <result pre="for malaria treatment and chemoprophylaxis and hydroxychloroquine is used for" exact="treatment" post="of several autoimmune conditions including rheumatoid arthritis. Both drugs"/>
 <result pre="azithromycin (a macrolide with anti-inflammatory properties) have been recommended for" exact="treatment" post="of hospitalized COVID-19 patients in several countries. However, due"/>
 <result pre="conditions such as CRS, sHLH and IRIS. Early recognition and" exact="treatment" post="of hosts who display the hallmarks of CRS, sHLH"/>
 <result pre="clinical trials globally. Experiences derived from therapeutics employed for the" exact="treatment" post="of complications secondary to immunotherapies, such as CAR-T, bispecific"/>
 <result pre="Y., Li B., Hu Y., et al. Clinical features and" exact="treatment" post="of COVID-19 patients in northeast Chongquing [published online ahead"/>
 <result pre="antigen receptor T-cell therapy for acute lymphoblastic leukemiaCancer Discov6201666467927076371 11BoulougouraA.SeretiI.HIV" exact="infection" post="and immune activation: the role of coinfectionsCurr Opin HIV"/>
 <result pre="for influenza A (H5N1) infectionN Engl J Med35720071450145117914053 29HungI.F.ToK.K.LeeC.K.LeeK.L.ChanK.YanW.W.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
 <result pre="distress syndrome: a review of current literature and potential future" exact="treatment" post="optionsClin Transl Med820192531512000 41TheryC.WitwerK.W.AikawaE.AlcarazM.J.AndersonJ.D.AndriantsitohainaR.Minimal information for studies of extracellular"/>
 <result pre="MISEV2014 guidelinesJ Extracell Vesicles720181535750 42RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet395202047347532043983 43World Health Organization. Clinical management"/>
 <result pre="injuryLancet395202047347532043983 43World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected. 27 May"/>
 <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected. 27 May 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected 44CaoB.WangY.WenD.LiuW.WangJ.FanG.A trial of"/>
 <result pre="56GerdemannU.KeirnanJ.M.KatariU.L.YanagisawaR.ChristinA.S.HuyeL.E.Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and" exact="treatment" post="of viral infectionsMol Ther20820121622163222801446 57HanajiriR.SaniG.M.HanleyP.J.SilveiraC.G.KallasE.G.KellerM.D.Generation of Zika virus-specific T"/>
</results>
